Isotoxic Intensity Modulated Radiotherapy (IMRT) in Stage III Non Small Cell Lung Cancer (NSCLC) - A Feasibility Study
This study is for patients having a course of chest radiotherapy treatment after receiving chemotherapy for the treatment of non-small cell lung cancer. Patients with non-small cell lung cancer have a risk of the tumour in the lung recurring or progressing after treatment.
In this study, we will investigate:
- whether giving a more targeted and individualised type of chest irradiation or radiotherapy to the lung tumour (known as Isotoxic IMRT), is practical and whether it causes side effects which can be tolerated
- whether this new method of delivering the radiotherapy can reduce the risk of the tumour in the lung recurring or progressing
- whether survival can be improved by using this new radiotherapy method
The dose of chest irradiation will be calculated specifically to suit patient's body shape, the position of the lung cancer, and how close healthy tissues are to the tumour. Radiotherapy will be delivered twice a day over a maximum period of 4.5 weeks. The duration of treatment will vary individually according to the delivered dose to the tumour area.
Non Small Cell Lung Cancer
Radiation: Intensity Modulated Radiotherapy treatment
|Study Design:||Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Isotoxic Intensity Modulated Radiotherapy (IMRT) in Stage III Non Small Cell Lung Cancer (NSCLC) - A Feasibility Study|
- The number of participants treated with isotoxic RT (to dose >60 Gy EQD2) using IMRT & hyperfractionated accelerated RT. [ Time Frame: Stage 1 (12 months) - after 19 patients have been treated with isotoxic IMRT ] [ Designated as safety issue: No ]Radiotherapy treatment plans & OAR tolerance doses will be analysed to assess the feasibility of delivering the proposed treatment.
- The number of participants from the study population who are suitable to receive isotoxic IMRT treatment. [ Time Frame: 12 months ] [ Designated as safety issue: No ]Stage 1 - if 13/19 patients can be planned to a dose of >60 Gy EQD2 the study will proceed to stage 2 and recruit a further 16 patients. Assessed via RT planning data.
- The number of participants treated with isotoxic IMRT who experience grade 3+ pulmonary toxicity [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]Stage 1 - if <3/19 participants experience grade 3+ acute pulmonary toxicity the study will proceed to stage 2 and recruit a further 16 patients. Assessed via toxicity data.
- The number of participants treated with isotoxic IMRT who experience acute grade 3+ non haematological toxicity & other late toxicities [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]To assess via toxicity data, the number of patients who experience grade 3+ non haematological toxicities and other late toxicities
- Number of participants whose disease is controlled locally & overall survival rates [ Time Frame: Follow up visits every 4 months for 2 years & then 6 monthly for up to 5 years ] [ Designated as safety issue: No ]After completion of radiotherapy treatment regular follow up will continue and data on long term toxicity, local control and survival will be collected.
|Study Start Date:||April 2014|
|Estimated Study Completion Date:||April 2021|
|Estimated Primary Completion Date:||April 2016 (Final data collection date for primary outcome measure)|
Experimental: Thoracic radiotherapy
Intensity Modulated Radiotherapy treatment (delivered twice daily on consecutive weekdays over 4.5 weeks)
Radiation: Intensity Modulated Radiotherapy treatment
Intensity Modulated Radiotherapy treatment
Approximately 12,000 patients are diagnosed with stage III NSCLC in the UK each year and their survival is ~15% at 5 years. As the majority of patients are not suitable for the gold standard treatment (concurrent chemo-radiotherapy (CTRT), novel strategies integrating radiotherapy (RT) technological advances and radiobiological knowledge need to be evaluated in patients treated with the alternative treatment option, sequential CTRT. There is solid evidence that improving local control in lung cancer leads to increased survival. Strategies to improve local control in stage III NSCLC include dose escalation and individualisation which are limited by the dose delivered to surrounding normal tissues. We hypothesise that this will be facilitated by the use of IMRT.
To demonstrate the feasibility of delivering isotoxic RT using IMRT and hyperfractionated accelerated RT in stage III NSCLC patients who are not suitable for concurrent CTRT.
Primary endpoint: Delivery of isotoxic IMRT to dose >60 Gy EQD2 (total biologically equivalent in 2 Gy fraction).
Secondary endpoints: Estimation of the suitability for lung isotoxic IMRT, estimation of proportion of patients with acute grade 3+ non haematological toxicity, estimation of late toxicity, estimation of local control/overall survival and development of a robust Quality Assurance (QA) process for lung IMRT.
Prospective multicentre, non-randomised feasibility study with early stopping rules.
35 patients will be recruited in this prospective multicentre feasibility study. Stopping rules are in place to ensure the safety of patients. We estimate that this regimen would be of added value to a national randomised phase II trial if 80% of the patients can be planned to a dose >60 Gy EQD2.
Patients with stage III NSCLC, PS 0-2, not suitable for concurrent CTRT, will be treated with individualised doses of radiation based on pre-specified normal tissue doses (spinal cord, brachial plexus, lung tissue, heart and great vessels/proximal bronchial tree). Radiotherapy will be delivered twice-daily over a maximum period of 4.5 weeks using IMRT and the dose of radiation will be increased until one or more of the organs at risk tolerance or the maximum dose of 79.2 Gy is reached.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01836692
|Contact: Corinne Faivre-Finn, MD PhD||0044 161 446 firstname.lastname@example.org|
|Contact: Sally Falk||0044 161 918 email@example.com|
|Belfast Health & Social Care NHS Trust - Northern Ireland Cancer Centre||Not yet recruiting|
|Belfast, United Kingdom|
|Principal Investigator: Gerard Hanna|
|Cambridge University Hospitals NHS Foundation Trust - Addenbrookes Hospital||Not yet recruiting|
|Cambridge, United Kingdom|
|Principal Investigator: Susan Harden|
|Beatson West of Scotland Cancer Centre||Not yet recruiting|
|Glasgow, United Kingdom|
|Principal Investigator: Stephen Harrow|
|Leeds Teaching Hospitals NHS Trust - St James's University Hospital||Not yet recruiting|
|Leeds, United Kingdom|
|Principal Investigator: Kevin Franks|
|The Christie NHS Foundation Trust||Recruiting|
|Manchester, United Kingdom|
|Principal Investigator: Corinne Faivre-Finn, MD PhD|
|Sheffield Teaching Hospitals NHS Foundation Trust - Weston Park Hospital||Not yet recruiting|
|Sheffield, United Kingdom|
|Principal Investigator: Matthew Hatton|
|The Royal Marsden NHS Foundation Trust||Not yet recruiting|
|Surrey, United Kingdom|
|Principal Investigator: Fiona McDonald|
|Principal Investigator:||Corinne Faivre-Finn, MD PhD||Christie Hospital NHS Foundation Trust|